<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182206</url>
  </required_header>
  <id_info>
    <org_study_id>1199.3</org_study_id>
    <nct_id>NCT02182206</nct_id>
  </id_info>
  <brief_title>An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours</brief_title>
  <official_title>A Phase I Open Label Dose Escalation Study of Continuous Once-daily or Twice Daily Oral Treatment With BIBF 1120 in Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120,
      pharmacodynamic parameters (Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI))
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of BIBF 1120</measure>
    <time_frame>Up to 7 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and intensity of Adverse Events according to common toxicity criteria (CTC) associated with increasing doses of BIBF 1120</measure>
    <time_frame>Up to 7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfer constant (Ktrans)</measure>
    <time_frame>Screening, day 2, 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extravascular-extracellular leakage volume (ve)</measure>
    <time_frame>Screening, day 2, 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the gadolinium concentration time curve [0-60 seconds] (AUC[Gd])</measure>
    <time_frame>Screening, day 2, 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative blood volume (rBV)</measure>
    <time_frame>Screening, day 2, 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean transit time (MTT)</measure>
    <time_frame>Screening, day 2, 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative blood flow (rBF)</measure>
    <time_frame>Screening, day 2, 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of tumour showing contrast uptake</measure>
    <time_frame>Screening, day 2, 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of tumour showing no contrast uptake</measure>
    <time_frame>Screening, day 2, 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restricted diffusion</measure>
    <time_frame>Screening, day 2, 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vessel size index</measure>
    <time_frame>Screening, day 2, 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eastern Cooperative Oncology Group (ECOG) performance score</measure>
    <time_frame>Baseline, up to 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumour responses according to the response evaluation criteria in solid tumour (RECIST)</measure>
    <time_frame>Baseline, up to 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve following the first dose of uniform intervals τ over the time interval from zero to 24 hours (AUCτ,1)</measure>
    <time_frame>up to 24 hours after the first dose on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve over the time interval from zero to the time of the last quantifiable drug concentration (AUC0-tz)</measure>
    <time_frame>up to 24 hours after the first dose on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve over the time interval from zero extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>up to 24 hours after the first dose on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured plasma concentration following the first dose of uniform intervals τ (Cmax,1)</measure>
    <time_frame>up to 24 hours after the first dose on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum plasma concentration following the first dose of uniform intervals τ (tmax,1)</measure>
    <time_frame>up to 24 hours after the first dose on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>up to 24 hours after the first dose on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRTpo)</measure>
    <time_frame>up to 24 hours after the first dose on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>up to 24 hours after the first dose on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase (Vz/F)</measure>
    <time_frame>up to 24 hours after the first dose on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve over the dosing interval τ (24 h) at steady state (AUCτ,ss)</measure>
    <time_frame>up to 24 hours after drug administration on day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose plasma concentration at steady state immediately before dosing (Cpre,ss)</measure>
    <time_frame>up to 24 hours after drug administration on day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration at steady state over the dosing interval τ (Cmax,ss)</measure>
    <time_frame>up to 24 hours after drug administration on day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum plasma concentration at steady state over the dosing interval τ (tmax,ss)</measure>
    <time_frame>up to 24 hours after drug administration on day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life at steady state (t1/2,ss)</measure>
    <time_frame>up to 24 hours after drug administration on day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance at steady state (CL/F,ss)</measure>
    <time_frame>up to 24 hours after drug administration on day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time at steady state (MRTpo,ss),</measure>
    <time_frame>up to 24 hours after drug administration on day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase at steady state (Vz/F,ss)</measure>
    <time_frame>up to 24 hours after drug administration on day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (RA)</measure>
    <time_frame>up to 24 hours after drug administration on day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum measured plasma concentration following the first dose of uniform intervals τ (Cmin,1)</measure>
    <time_frame>up to 24 hours after the first dose on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from first dosing to the minimum plasma concentration over the dosing interval τ (tmin,1)</measure>
    <time_frame>up to 24 hours after the first dose on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum measured plasma concentration at steady state over the dosing interval τ (Cmin,ss)</measure>
    <time_frame>up to 24 hours after drug administration on day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from last dosing to the minimum plasma concentration at steady state over the dosing interval τ (tmin,ss)</measure>
    <time_frame>up to 24 hours after drug administration on day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose concentration of the 15th dose over the dosing interval τ (Cpre,15)</measure>
    <time_frame>pre-dose on day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>BIBF 1120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120</intervention_name>
    <arm_group_label>BIBF 1120</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with confirmed diagnosis of advanced, non resectable and/or
             metastatic solid tumours, who have failed conventional treatment, or for whom no
             therapy of proven efficacy exists, or who were not amenable to established forms of
             treatment

          -  Measurable tumour deposits by one or more techniques (X-ray), Computed Tomography
             (CT), Magnetic Resonance Imaging (MRI))

          -  At least one tumour lesion considered suitable for DCE-MRI as determined by discussion
             with centre radiologist. This lesion must not have been previously irradiated

          -  Age 18 years or older

          -  Life expectancy of at least three months

          -  Written informed consent given consistent with International Conference on
             Harmonisation-Good Clinical Practice (ICH-GCP) guidelines

          -  Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1

          -  Patients completely recovered from any therapy-related toxicities from previous
             chemo-, hormone-, immuno-, or radiotherapies

        Exclusion Criteria:

          -  Surgical procedures within four weeks of initiating treatment with the study drug,
             active ulcers, or injuries with incomplete wound healing

          -  Active infectious disease

          -  Uncontrolled, severe hypertension (diastolic BP (Blood Pressure) &gt;100 mmHg, Systolic
             BP&gt;180 mmHg)

          -  Gastrointestinal disorders that might have interfered with the resorption of the study
             drug

          -  Serious illness or concomitant non-oncological disease considered by the investigator
             to have been incompatible with the protocol

          -  Brain metastases requiring therapy

          -  Absolute neutrophil count less than 1500/mm3

          -  Platelet count less than 100 000/mm3

          -  Bilirubin greater than 1.5 mg/dl (&gt;26 μmol/L, System International (SI) unit
             equivalent)

          -  Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater
             than three times the upper limit of normal (if related to liver metastases greater
             than five times the upper limit of normal)

          -  Serum creatinine greater than 1.5 mg/dl (&gt;132μmol/L, SI unit equivalent)

          -  Women and men who were sexually active and unwilling to use a medically acceptable
             method of contraception

          -  Pregnancy or breastfeeding

          -  Treatment with other investigational drugs; chemotherapy or hormone therapy (excluding
             Lutenizing Hormone Releasing Hormone (LHRH) agonists or bisphosphonates provided the
             lesion for MR (magnetic resonance) imaging did not arise from bone) or participation
             in another clinical study within the past four weeks before start of therapy or
             concomitantly with this study

          -  Patients unable to comply with the protocol

          -  Active alcohol or drug abuse

          -  History of autoimmune disease

          -  History of allergy to gadolinium or other intravenous (IV) contrast agent, indwelling
             medical devices or any other condition that would preclude MR scanning

          -  Patients requiring the ongoing use of dexamethasone, anti-histamines,
             anti-hypertensives or medications for the control of cardiac failure such as
             diuretics, where there was likely to be a need for alteration of dose during the study
             period. Dose adjustment of such medications may have independently altered vascular
             permeability or blood flow
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

